| HST |
Report |
Comparable RevPAR (Q2 2026) |
BEAT |
pred ~$252 vs. cons $248.07 |
MEDIUM |
| HST |
Report |
Comp. Hotel EBITDA Margin (Q2 2026) |
BEAT |
pred ~32.2% vs. cons 31.58% |
MEDIUM |
| HST |
Report |
AFFO per Share (Q2 2026) |
BEAT |
pred ~$0.64 vs. cons $0.619 |
MEDIUM |
| HST |
Guide |
FY 2026 Adj. EBITDAre (FY 2026) |
BETTER |
guide ~$1,845M midpoint vs. cons $1,813.9M |
MEDIUM |
| HST |
Guide |
FY 2026 Comp. RevPAR Growth (FY 2026) |
BETTER |
guide ~4.25% midpoint vs. cons ~3.5% implied |
MEDIUM |
| HST |
Guide |
H2 2026 RevPAR Tone (H2 2026) |
UNCHANGED |
guide 'low single digits' maintained with slight upward bias vs. cons ~2-3% |
HIGH |
| HST |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.0% |
— |
MEDIUM |
| HST |
Return |
5-day cumulative residual |
-2.5% (FADE) |
FADE — beat + raise already priced into +15% run since Q1; H2 language cautious; short-cover provides floor vs. worst A-quarter outcomes |
MEDIUM |